Ditchcarbon
  • Contact
  1. Organizations
  2. Daewoong Pharmaceutical
Public Profile
Pharmaceutical Preparation Manufacturing
IN
updated 18 days ago

Daewoong Pharmaceutical Sustainability Profile

Company website

Daewoong Pharmaceutical Co., Ltd., commonly referred to as Daewoong, is a leading South Korean pharmaceutical company headquartered in Incheon, South Korea. Established in 1945, Daewoong has made significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and marketing of innovative medicines. The company operates extensively across Asia, Europe, and the Americas, with a diverse portfolio that includes prescription drugs, over-the-counter products, and biopharmaceuticals. Notable for its commitment to innovation, Daewoong has developed unique therapies in areas such as gastroenterology, neurology, and endocrinology. With a strong market position, Daewoong has achieved several milestones, including the successful launch of its biosimilar products, which have garnered recognition for their quality and efficacy. As a forward-thinking organisation, Daewoong Pharmaceutical continues to contribute to global health advancements.

DitchCarbon Score

How does Daewoong Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Daewoong Pharmaceutical's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

Let us know if this data was useful to you

Daewoong Pharmaceutical's reported carbon emissions

In 2024, Daewoong Pharmaceutical reported total carbon emissions of approximately 32,500,000 kg CO2e, comprising about 9,675,000 kg CO2e from Scope 1 and about 23,296,000 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2023, where total emissions were around 34,706,000 kg CO2e, with Scope 1 emissions at approximately 10,184,000 kg CO2e and Scope 2 emissions at about 24,522,000 kg CO2e. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Daewoong Pharmaceutical has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which may limit its ability to demonstrate a proactive approach to climate commitments. Overall, Daewoong Pharmaceutical's emissions data reflects its ongoing operations in the pharmaceutical sector, with a focus on managing its direct and indirect emissions. The absence of reduction targets suggests that the company may need to enhance its climate strategy to align with industry standards and expectations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20202021202220232024
Scope 1
-
0,000,000
00,000,000
00,000,000
0,000,000
Scope 2
35,843,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-

How Carbon Intensive is Daewoong Pharmaceutical's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Daewoong Pharmaceutical's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Daewoong Pharmaceutical's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Daewoong Pharmaceutical is in IN, which has a very high grid carbon intensity relative to other regions.

Daewoong Pharmaceutical's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Daewoong Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Daewoong Pharmaceutical's Emissions with Industry Peers

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Losan Pharma GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 11 hours ago

Revance Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Bruschettini Srl

IT
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Sinco Pharma

CN
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy